INTRODUCTION
regardless of the presence of diabetes [2] .
The IDSA guideline for erysipelas or cellulitis recommends ''dicloxacillin, cephalexin, clindamycin, or erythromycin, unless streptococci or staphylococci resistant to these agents are common in the community'' [3] . The IDSA guidelines were published in 2005 and an update will not be ready until late 2013 [4] .
The more recent (published 2011) IDSA guidelines for MRSA recommend empirical (MRSA) coverage only for purulent cellulitis [5] . In 2007, the Centers for Disease Control published similar guidelines for skin and softtissue infections that included endorsement by IDSA and the American Medical Association [6] .
Empirical MRSA coverage for non-purulent cellulitis is not recommended unless a therapeutic failure has occurred. These guidelines also suggest that empirical (MRSA) coverage for complicated skin and soft-tissue infections be considered in hospitalized patients.
MRSA has become common in the United
States and is more prevalent than methicillinsensitive Staphylococcus aureus (MSSA) in many communities [7] . Many, if not most physicians, routinely cover for MRSA using trimethoprim/ sulfamethoxazole (TMP/SMX), clindamycin, doxycycline or fluoroquinolones in patients with cellulitis [8] . Some authors advocate empirical coverage of cellulitis when the skin is intact [9] . Others suggest that empirical therapy for CAMRSA be limited to seriously ill patients or those who have failed initial empirical therapy [10] . Still others recommend such coverage when the community prevalence is high, such as greater than 10-15% [7, 11] . Is that appropriate in 2013? Should diabetics with cellulitis always receive empirical coverage for MRSA?
METHODS
PubMed was searched for the terms ''cellulitis,'' ''MRSA,'' ''skin and soft tissue infection,'' ''community acquired staphylococcus'' and combinations of these terms during the month of May, 2013. The results were narrowed by omitting articles not in English and those with terms including ophthalmic, systemic, case studies, hospitalized, and purulent. Additional articles were added in October as a result of reviewer's comments.
The analysis in this article is based on previously conducted studies, and does not involve any new studies of human or animal subjects performed by any of the authors.
WHAT IS CELLULITIS?
What is and what is not cellulitis is important in determining a possible microbiological etiology and treatment. Unfortunately, cellulitis is often used to describe a broad group of superficially similar (e.g., diffuse and spreading) but often histologically distinct skin infections. The International Classification of Diseases version 9 (ICD-9) creates further confusion by combining cellulitis and abscess under a single code [12] .
Cellulitis Although both infections are generally similar in surface appearance, the border of erysipelas is sharply demarcated and raised whereas the border of cellulitis is diffuse and flush with surrounding skin. Systemic effects as described above may also occur with erysipelas. According to some authors, erysipelas and cellulitis may coexist at the same site making differentiation difficult. Erysipelas also usually affects children and the elderly whereas cellulitis occurs in all age groups. The etiologic agent of erysipelas is believed to be almost always streptococci [3, 12, 15, 17] . burns, deep-tissue infections, major abscesses, infected ulcers, and perirectal abscesses [18] .
Some skin conditions mimic cellulitis and have been referred to as ''pseudo-cellulitis'' [19] . These include allergic dermatitis, contact dermatitis, thrombophlebitis and DVT, panniculitis and erythema migrans.
PATHOGENESIS AND MICROBIOLOGY
There is relatively little information in the literature about the pathogenesis of cellulitis. Most cases result from microbial invasion through a breach in the skin. Lacerations, bite or puncture wounds, scratches, instrumentation (e.g., needles), pre-existing skin conditions or infections (e.g., chicken pox, impetigo, or ulcer), burns, and surgery are more among the common portals of entry. In many cases the skin breaks are not clinically apparent [3, 13, 15] . Bacteremia may contribute to some cases of cellulitis. The most common site of infection is the lower extremities (up to 70-88% of cases) [3, 13, 14, 20] . Fissured webbing of the toes from maceration, dermatophyte infection, or inflammatory dermatoses is believed to contribute in many cases [3, 13, 15, 21] .
A number of risk factors have been identified for both initial and recurrent episodes of lower extremity cellulitis. These include obesity, chronic edema from venous insufficiency or lymphatic obstruction, previous cellulitis, saphenectomy, and skin barrier disruption especially web toe intertrigo [3, 13, 15, [21] [22] [23] [24] . Other putative factors include smoking, previous surgery, and previous antibiotic use [22] .
Edema is a major contributor to the development of cellulitis by creating small, unapparent breaks in the skin. Swollen cutaneous surfaces are also taut, fragile, and more easily disrupted with minor trauma than normal skin. The role of lymphatic obstruction may relate to the inability to clear the pathogen. Venous insufficiency may also cause ''venous eczema'' or stasis dermatitis which could disrupt the cutaneous barrier. More obvious breaches in the form of stasis ulcers are also possible. The role of obesity may be difficult to separate from edema since the two often go hand in hand. Adipose tissue, however, can compress lymphatic channels and impair lymphatic flow. Obesity may also increase skin fragility and decrease hygiene levels [13] .
Groups A, B, C, and G streptococci and Staphylococcus aureus are considered to be the most common etiologic agents of cellulitis [3, 13, 15, 16] .
Depending [3, 13, 15, 16, 25] . Biopsy of skin with cellulitis has shown dilated lymphatics and capillaries, marked dermal edema, and primarily neutrophilic infiltration, either diffusely within the dermis or concentrated around vessels [13] . The bacterial burden from central and peripheral biopsy is usually low suggesting an exaggerated inflammatory response to low concentrations of microorganisms or possibly their export products [26] . It has been suggested that exotoxins elaborated by streptococci or staphylococci are really the primary mediators of inflammation.
This theory proposes that immune responses to exotoxins are responsible for most of the tissue effects seen in cellulitis as opposed to direct cytotoxic effects of the exotoxins. In other words, the exotoxin would function as a superantigen [13, 27] .
CULTURE ETIOLOGY
Most cases of cellulitis are not amenable to identification of a pathogen [3, 7, 13, 15] .
Microbiological cultures are usually negative for the majority of cases in which cultures are performed [8] .
A study of quantitative cultures of biopsy specimens from cutaneous cellulitis found that only 28.5% and 18% of needle aspiration and punch biopsy cultures were positive, respectively [26] .
Other studies have shown blood cultures were even less likely to be positive with yields \5% [28] [29] [30] . Slightly higher yields (up to 7-10%) have been reported for patients who had not previously received antimicrobial therapy [13] . As a result, cultures of nonsuppurative cellulitis are rarely formed, and treatment is informed by expert guidelines and clinical judgment. The overall body of evidence suggests that streptococci are the most common single pathogen in cellulitis [3, 12, 13, 15] . These bacteria may either cause or contribute to up to 75-90% of cases [13] . However, there are some recent reports that continue to disagree with this conclusion [9, 31] . Nevertheless, there seems to be a general agreement that cases of suppurative (or purulent) cellulitis and those associated with penetrating trauma or injection drug use are more likely to have a staphylococcal etiology [12, 15] . Yet, surgical drainage for purulent abscesses has long been the mainstay of therapy for such infections, most of which resolve without ancillary antimicrobial therapy [32] . The role of empirical therapy in these patients remains undetermined. Communityassociated MRSA (CAMRSA) is probably a minor contributor to non-suppurative cases of cellulitis if at all [12, 13] . Gunderson [8, 12] . It also reinforces the recommendation against empirical coverage for MRSA in nonsuppurative cellulitis [5] . This study included a few animal bites and 40% had a defined portal of entry.
STUDIES OF EMPIRICAL COVERAGE FOR CELLULITIS
The second trial by Pallin was published in 2013 [8] . This randomized, double-blind, multicenter study evaluated 146 patients (both adults and children). Cephalexin (from 300 mg QID to 1 g QID) plus placebo (control group) was administered to half of the patients (73). without evidence of streptococcal infection. Nearly 28% of the study patients had diabetes mellitus. MRSA colonization was not evaluated.
Jenkins and associates retrospectively reviewed discharged patients from a Denver hospital for 2007 using ICD-9 coding data for SSTIs [35] . The primary outcome of interest was treatment failure. They noted that 85% of patients with cellulitis received anti-MRSA therapy, and nearly half were discharged on a regimen of TMP/SMX. The failure rate for cellulitis was 12%. Most patients were treated with broad-spectrum antibacterial agents, and for a median duration of nearly 2 weeks. The authors suggested SSKI patients would be appropriate for antimicrobial stewardship programs.
Jenkins and associates [36] 
STUDY OF PROPHYLACTIC ANTIBIOTICS FOR RECURRENT CELLULITIS
A double-blind randomized, controlled trial by Thomas et al. [37] was published in 2013. This multicenter study evaluated 274 patients with a history of at least 2 previous cases of cellulitis of the leg within the previous 3 years. One hundred and thirty-six patients received penicillin V 250 mg bid for 12 months while The anti-streptococcal activity of trimethoprimsulfamethoxazole and doxycycline has been described as ''uncertain'' [38] . Early data published at the time of FDA approval in 1973 indicated a very low MIC of 0.05/1 mcg/ml for the trimethoprim and sulfamethoxazole components, respectively [39] . Despite the impressive in vitro data, a randomized, double-blind study published in 1973 showed trimethoprim-sulfamethoxazole was inferior to penicillin G in the treatment of group A streptococcal pharyngitis and tonsillitis [40] . A 1999 in vitro study by Kaplan of Streptococcus pyogenes isolates was discontinued early because of a high rate of resistance to trimethoprim-sulfamethoxazole [41] . A recent in vitro study evaluating trimethoprimsulfamethoxazole activity against Streptococcus pyogenes showed susceptibility was dependent on the media used for culture [42] . Again, it may be reasonable to cover diffuse, nonpurulent cellulitis with beta lactams only. Could diabetics with non-suppurative infection of the lower extremities receive monotherapy with a beta lactam? It may be reasonable for those provided the skin is intact. Non-infected ulcers are unlikely to be associated with a surrounding cellulitis. The 2012 IDSA diabetic foot guidelines did not address this situation [38] .
The current (2005) practice guidelines for management of SSTIs can be found at the IDSA website [43] .
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